Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 182.1 - -
Change - -69.05% 63.28% 110.34% -13.65% 39.71% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 167.1 171.9 182.1
Change - -69.05% -16.19% 226.78% -9.5% 53.4% 2.84% 5.97%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -4.39x -6.8x 43.1x
PBR - - 2.55x 6.18x 6.41x 8.98x 16.5x -
PEG - 0x 0.2x -0.2x 0.1x 0.57x 0.2x -0x
Capitalization / Revenue 1,803x - - - - - 54.8x 5.01x
EV / Revenue 1,803x - - - - - 51.8x 5.01x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -7.1x -10.8x -8.83x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -4.76x -6.4x 37.8x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -8.23x -36.7x -
FCF Yield -16.6% - -68.5% -20.8% -21.9% -12.1% -2.72% -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.36 -0.2325 0.0367
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 3.321 36.32
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -23.54 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -35.09 -26.87 4.821
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -35.21 -30.57 -8.68
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 1.580 1.580 1.580
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 115,272 - -
Announcement Date 23/3/22 28/3/23 1/4/24 31/3/25 31/3/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-4.39x - -7.1x - 130M
35.1x6.14x18.98x0.94% 50.35B
-23.1x337.19x-21.24x-.--% 39.21B
25.17x2.79x12.05x-.--% 34.52B
46.88x4.72x30.24x-.--% 34.6B
27.13x7.96x19.97x0.42% 27.05B
31.25x5.03x22.91x-.--% 15.11B
24.07x2.05x9x1.11% 13.85B
24.32x1.93x11.7x-.--% 13.18B
Average 20.71x 45.98x 10.72x 0.31% 25.33B
Weighted average by Cap. 22.86x 62.03x 12.06x 0.32%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.